JP2024506384A5 - - Google Patents

Info

Publication number
JP2024506384A5
JP2024506384A5 JP2023548873A JP2023548873A JP2024506384A5 JP 2024506384 A5 JP2024506384 A5 JP 2024506384A5 JP 2023548873 A JP2023548873 A JP 2023548873A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2024506384 A5 JP2024506384 A5 JP 2024506384A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
roflumilast
ophthalmic pharmaceutical
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015942 external-priority patent/WO2022173923A1/en
Publication of JP2024506384A publication Critical patent/JP2024506384A/ja
Publication of JP2024506384A5 publication Critical patent/JP2024506384A5/ja
Pending legal-status Critical Current

Links

JP2023548873A 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法 Pending JP2024506384A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163148008P 2021-02-10 2021-02-10
US63/148,008 2021-02-10
US202163261404P 2021-09-20 2021-09-20
US63/261,404 2021-09-20
PCT/US2022/015942 WO2022173923A1 (en) 2021-02-10 2022-02-10 Methods for ophthalmic delivery of roflumilast

Publications (2)

Publication Number Publication Date
JP2024506384A JP2024506384A (ja) 2024-02-13
JP2024506384A5 true JP2024506384A5 (https=) 2025-02-19

Family

ID=82704332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548873A Pending JP2024506384A (ja) 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法

Country Status (8)

Country Link
US (2) US12102622B2 (https=)
EP (1) EP4291162A4 (https=)
JP (1) JP2024506384A (https=)
AU (1) AU2022218993A1 (https=)
CA (1) CA3206106A1 (https=)
IL (1) IL304924A (https=)
MX (1) MX2023009352A (https=)
WO (1) WO2022173923A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
AU2023341161A1 (en) * 2022-09-16 2025-04-03 Iolyx Therapeutics, Inc. High concentration pharmaceutical compositions of roflumilast for ophthalmic delivery
WO2025024684A1 (en) * 2023-07-25 2025-01-30 Iolyx Therapeutics, Inc. Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59410119D1 (de) 1993-07-02 2002-06-20 Byk Gulden Lomberg Chem Fab Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20040242597A1 (en) 2001-09-19 2004-12-02 Thomas Klein Combination
PT1511516E (pt) 2002-05-28 2009-02-20 Nycomed Gmbh Preparação farmacêutica para aplicação tópica
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
AU2005267706B2 (en) 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
US8663694B2 (en) * 2005-03-16 2014-03-04 Takeda Gmbh Taste masked dosage form containing roflumilast
DK1906916T3 (da) * 2005-05-10 2009-01-19 Alcon Inc Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser
BRPI0609227A2 (pt) 2005-05-10 2010-03-09 Alcon Inc composições de suspensão de nepafenac e outros fármacos oftálmicos, bem como uso das referidas composições no tratamento tópico de distúrbios oftálmicos
EP1889620A4 (en) * 2005-06-09 2008-12-10 Santen Pharmaceutical Co Ltd EYE DROPS CONTAINING ROFLUMILAST
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
CA2712017C (en) 2008-01-18 2016-08-09 Oxagen Limited Compounds having crth2 antagonist activity
RS54413B1 (sr) 2008-08-22 2016-04-28 Sanofi [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze iz mastocita
EP2506878A2 (en) 2009-12-03 2012-10-10 Lupin Limited Process for preparing pharmaceutical ophthalmic compositions
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014072937A1 (en) 2012-11-08 2014-05-15 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
MX2021003633A (es) 2018-10-16 2021-05-27 Res Triangle Inst Dispositivo de depósito biodegradable subcutáneo.
EP4061332A4 (en) 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
WO2023049809A1 (en) * 2021-09-22 2023-03-30 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Similar Documents

Publication Publication Date Title
EP3681500B1 (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
Rashad Laser in situ keratomileusis for myopic anisometropia in children
JP2024506384A5 (https=)
JP2006524185A5 (https=)
JP2015509500A5 (https=)
JP6014033B2 (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
Stojanovic et al. 200 Hz flying-spot technology of the LaserSight LSX excimer laser in the treatment of myopic astigmatism: six and 12 month outcomes of laser in situ keratomileusis and photorefractive keratectomy
CN109996814A (zh) 多激酶抑制剂及在眼部纤维化中的用途
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
JP2015523986A5 (https=)
RU2014151992A (ru) Лечение воспалительных заболеваний глаз с применением лахинимода
RU2707379C1 (ru) Способ выбора параметров лазерного воздействия при лечении далекозашедшей и терминальной рефрактерной глаукомы
Zheng et al. Angle-closure glaucoma following periorbital botulinum toxin injection.
RU2668703C1 (ru) Способ хирургического лечения первичной открытоугольной глаукомы
RU2164112C1 (ru) Способ лечения постконтузионных повреждений глаза
RU2743218C1 (ru) Способ хирургической коррекции пресбиопии у лиц среднего и пожилого возраста - тканесохранный ЛАСИК
Sakai et al. Recurrent uveal effusion after laser iridotomy
Espana et al. Cyclodialysis cleft secondary to removal of an anterior chamber phakic intraocular lens
RU2585400C2 (ru) Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола
US20250387331A1 (en) Prostaglandin analogs and methods for sustained glaucoma management
RU2688960C1 (ru) Способ комбинированного хирургического лечения вторичной глаукомы, вызванной эмульгированием силикона
RU2294183C2 (ru) Способ проведения операции рефракционно-коррегирующей эксимерлазерной интрастромальной кератэктомии (рэик)
Abdurakhmanovich et al. Results of Staged Combined Laser Treatment of Neovascular Glaucoma
RU2731885C2 (ru) Способ профилактики пигментной глаукомы при синдроме пигментной дисперсии
RU2638767C1 (ru) Способ профилактики реактивной гипертензии после факоэмульсификации катаракты